NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, sa.18, ss.1711-1723, 2020 (SCI-Expanded)
BackgroundOsimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.